Details of the Drug Combinations

General Information of This Drug (ID: DMHKCIS)

• Drug Name: Aldoxorubicin (DMHKCIS)
• Synonyms: 1361644-26-9; ALDOXORUBICIN; Doxorubicin-EMCH; 151038-96-9; Aldoxorubicin (USAN); CHEMBL2107818; SCHEMBL15221892; OBMJQRLIQQTJLR-LBMCFUDOSA-N; ZINC163337436; AKOS030526452; CS-1186; HY-16261; D10383; W-5595; (8S)-1-Methoxy-6,8alpha,11-trihydroxy-8-[1-[2-[6-(2,5-dioxo-3-pyrroline-1-yl)hexanoyl]hydrazono]-2-hydroxyethyl]-10alpha-(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyloxy)-7,8,9,10-tetrahydronaphthacene-5,12-dione

Indication

Soft tissue sarcoma; ICD 11: 2B57; Status: Phase 3 [1]; Glioblastoma multiforme; ICD 11: 2A00.0; Status: Phase 2 [2]; Pancreatic ductal carcinoma; ICD 11: 2C10.0; Status: Phase 2 [2]; Small-cell lung cancer; ICD 11: 2C25.Y; Status: Phase 2 [1]; Solid tumour/cancer; ICD 11: 2A00-2F9Z; Status: Phase 2 [3]

List of Combinatorial Drugs (CBD) Containing This Drug

2 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Gemcitabine + Aldoxorubicin	DC4WER4	Gemcitabine	Metastatic Solid Tumors	[4]
Ifosfamide + Aldoxorubicin	DCEDMNP	Ifosfamide	Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma	[5]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] ClinicalTrials.gov (NCT01580397) Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer. U.S. National Institutes of Health.
• [4] ClinicalTrials.gov (NCT02235688) Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors
• [5] ClinicalTrials.gov (NCT02235701) Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma